TTAM closed Friday at $16.52, down 1.6% on the week, and just days after a Q1 earnings print that came in light on both revenue and EPS.
The results set an interesting backdrop. Q1 EPS of $0.18 missed the $0.20 consensus estimate. Revenue of $398.4M fell fractionally short of the $399.7M forecast. The stock initially jumped nearly 6% the day after the announcement before giving most of that back. Titan reaffirmed its full-year guidance of low-single-digit revenue growth — keeping the bull case alive while not offering much fresh fuel. Still up 10.3% on the month, the stock has recovered meaningfully from its April lows.
The short side has been quietly rebuilding since the earnings event. Short interest has risen roughly 4% over the past week to approximately 3.64 million shares, reversing a sharper decline through mid-April when shorts fell from above 4 million shares — a drop of around 12% over the prior month. At 14.8% of the free float, short positioning is material enough to warrant attention, especially given the recent directional shift. The ORTEX short score has ticked up to 74 from the low-70s over the past ten days, signalling growing short-side pressure rather than a easing. The borrow market, however, remains far from stressed. Availability is ample at around 249% of current short interest — well above any meaningful squeeze threshold — and the cost to borrow has actually eased over the month to just over 1%, down from the 1.7% range seen in late March and early April.
Options traders lean defensive but not dramatically so. The put/call ratio sits at 1.46, modestly above its 20-day average of 1.33, with a z-score of just 0.55 — elevated but not at an extreme. The 52-week high on the PCR is 1.56, so current readings are high-end-normal rather than a sharp outlier. Most of the PCR drift higher has come in the past few weeks, coinciding with the earnings period; the mid-April reading dipped below 0.8, which now looks like a brief period of calm before cautious positioning resumed. The combined picture from shorts and options is one of wariness rather than aggression: shorts are rebuilding incrementally, and options traders are hedging, but neither metric is at a level that implies a strong directional conviction.
Analyst sentiment got a clear boost on Friday. Citigroup raised its price target on TTAM to $20 from $19, maintaining its Buy rating — a direct response to the earnings release. The mean price target across the Street is $17.64, implying roughly 7% upside from current levels. Jefferies is also at $20 with a Buy, while Bernstein sits at $17 with a Market Perform. Not everyone is onside: Bank of America rates the stock Underperform with a $14 target, and Stifel is at Hold with $15. The PE of 14.8x and EV/EBITDA near 7.9x are not demanding multiples for a mid-cap construction materials name, and both have drifted slightly lower over the past 30 days, keeping the valuation case reasonably intact. The 14-day RSI of 52.8 points to neutral momentum — no overbought or oversold read to anchor the short-term view.
One signal worth flagging is the CFO's open-market purchase in March. The CFO bought 20,000 shares at $14.93, a $298,600 outlay, when the stock was trading well below current levels. That purchase preceded both the earnings beat-then-reaffirmation sequence and a 10%-plus monthly recovery — making it the most clearly timed insider activity in the recent record. Parent company Titan S.A. continues to hold 86.7% of the company, leaving a thin free float and contributing structurally to the elevated SI-as-percentage-of-float reading.
Among peers, MLM fell 3.9% on the week and VMC dropped 4.6%, making TTAM's 1.6% decline look relatively contained. CRH fared better, off just 1.5%. The degree of sector-wide weakness adds context to TTAM's post-earnings resilience — the stock held its ground in a tough tape for construction materials names broadly. The key watchpoint from here is whether short interest continues its recent rebuild or stalls as the post-earnings narrative stabilises around the reaffirmed guidance and the fresh Citi target.
See the live data behind this article on ORTEX.
Open TTAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
